The high affinity immunoglobulin E receptor (FcelLl) and the B and T cell antigen receptors (TCK) are multimeric complexes containing subunits with cytoplasmic antigen recognition activation motifs (ARAMs). The presence of multiple motifs may be a way to amplify a single signal or provide independent activation modules. Here we have compared the signaling capacity of the same FceKI 3` motif in the context of two different receptors, FceKI and TCK/CD3, simultaneously reconstituted on the surface of the same ~'-deficient T cell line. Both reconstituted receptors mediate early (phosphorylation) and late (interleukin [IL]-2 release) signals. Mutation of the two tyrosine residues of ARAM 3` alters early signaling by both receptors, but the set of substrates phosphorylated via ARAM 3` is different for each receptor and is thus dependent on the receptor context. Furthermore, the mutations prevent FceKI-but not TCK/CD3-mediated IL-2 release. These data demonstrate that ARAM 3` is necessary for allowing both receptors to phosphorylate the complete set of substrates, and that the CD3 complex, unlike the FceKI chain, contains activation modules capable of compensating for the absence of a functional ARAM 3' in generating late signals such as IL-2 release.
T
he B and T cell antigen receptors (TCR/CD3), the high (Fc3,RI) and low (Fc~RIII/CD16) a~nity Fc receptors for IgG, and the high affinity Fc receptor for IgE (FceRI) belong to a class of multimeric receptors associated with nonreceptor tyrosine kinases (1-12). The activation of these kinases is one of the first steps in the signaling cascade, allowing the multimeric receptors to initiate various specialized functions. FceRI is a tetrameric complex formed by an IgE-binding c~ chain, a ~ chain, and a homodimer of 3` chains (13, 14) . The TCR/CD3 complex is also a multichain structure composed of the two antigen-binding oL and/~ chains, the three invariant chains 3`, ~, and E constituting the CD3 complex, and one of the six possible dimers formed by disulfide linkage between TCR ~', 71, and FceRI 3' chains (15) (16) (17) . The homodimers 3`3` and ~'" and the heterodimer 3`~" are also part of one Fc3' receptor (Fc3,RIII/CD16) and are therefore subunits common to Fc and T cell receptors (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) . The high level of homology between the transmembrane domains of 3' and ~" (26) may explain why these dimers associate equivalently with various receptor complexes and appear interchangeable. In addition, the presence of these 3/-or ~'-containing dimers 1 Both authors contributed equally to this work.
is required for efficient surface expression of the multimeric complexes (18, 21-23, 27, 28) .
The cytoplasmic tails of the FceRI 3`, ~', and ~/chains contain a common 18-amino acid motif named antigen recognition activation motif (ARAM) 2 (29) (30) (31) , which, when fused to the extracellular and transmembrane part of an unrelated transmembrane protein, confers receptor-like activity to the chimeric molecule (32) (33) (34) (35) (36) (37) (38) . Signaling through this motif is absolutely dependent on the presence of two intramotif tyrosines (3'4, [36] [37] [38] . ARAMs are also present in the 3`, ~, and e chains of CD3 and in the fl chain of Fcel~I (29) (30) (31) . The fact that ARAM ~" or ARAM 3/by itself is able to generate the various signals observed with the entire receptor raises the question of the function of the other ARAMs present in the same receptor. In the TCR it has been shown that two autonomous transduction modules exist: the ~'chain and the 3'6e chains (39) . A TCR with a truncated ~" chain devoid of ARAMs is able to induce IL-2 release via the CD3 com-plex. In the B cell antigen receptor, the ARAMs of Ig-a and Ig'B also control distinct signals (4). Similarly, the ~ and 3' chains of FceRI control different tyrosine kinases: fl binds Lyn of the Src family and 3' activates Syk of the Syk/ZAP-70 family (40) .
The FceRI 3, chains are part of at least four different types of receptors: FcyRI (41, 42) , Fc3'RIII (18, 21, 22) , FceRI (13, 14) , and TCR (17) . Some of these 3' chain-containing receptors are expressed concomitantly on the surface of the same cell. For example, FceRI and Fc3,RIII are both expressed on mast cells, and Fc3'RIII and TCR are expressed on subsets ofT cells. Therefore we wanted to address whether FceRI % and the FceRI 3, motif in particular, could function differently when part of different multimeric complexes. We have reconstituted two different 3' chain-containing complexes, FceRI and TCR, on the surface of the same cell, and have compared the signaling capacity of each 3' chain motif in the natural environment of their respective receptor. To avoid any interference from endogenous subunits, we have chosen to reconstitute these receptors in a T cell line deficient in ~', % and ~/chains (28) .
Materials and Methods
Cell Lines and Media. 2.M2 cells, a variant of the 2B4 mouse T cell line that lacks the ~" chain of the TCK (28) (kindly provided by R. Klausner, National Institutes of Health, Bethesda, MD), were cultured in RPMI-1640 with 10% (vol/vol) heat-inactivated fetal bovine serum (FBS), 50 #M B-ME and 2 mM t-glutamine. An Ib2-dependent T cell, CTLL (a gift of H. Rigger, National Cancer Institute, National Institutes of Health, Frederick, MD), was maintained in RPMI-1640 with 10% FCS, 2 mM t-glutamine, and 20 U/ml rhlL-2. The BW# ceils were previously described (39) . (Rockford, IL). The goat anti-mouse and goat anti-rabbit antibodies conjugated to alkaline phosphatase were from Jackson ImmunoResearch Labs, Inc. (West Grove, PA); the antiphosphotyrosine antibody 4G10 was from UBI (Lake Placid, NY); the anti-FceRI subunit antibody JRK and the anti-FceRI 3, subunit antiserum were described previously (43) .
Reagents and
12sI-iodination of BC4, an anti-rat FceRI ~ monoclonal antibody (kind gift of Reuben Siraganian, National Institute of Dental Research, National Institutes of Health) and 2Cll, a monoclonal anti-CD3e (kind gift of Jeffrey Bluestone, University of Chicago, Chicago, IL) was performed by use of chloramine T.
Mutants and Tmnsfectians. Point mutations in rat Fc~RI 3" cDNA were created via PCR. The full-length eDNA was amplified with a 5' primer (bp including the first ATG and a 3' primer (bp 289-172) starting after the stop codon, converting tyrosine (Y) residues to phenylalanine (F). 2.M2 cells were cotransfected by electroporation with rat FceRI ot and/3 cDNAs subcloned in pcDLSRc~ 296 (44) and with either the wild-type or the mutated form of rat 3, cDNA subdoned in pBJlneo (45) . Cells were grown under G418 (GIBCO BRL, Gaithersburg, MD) selection, and resistant clones were selected for FceRI and CD3 surface expression. BW8 cells were transfected with either the wild-type or the mutated form of rat 3, cDNA subcloned in pBJlneo.
Flow Cytometry Analysis. Flow cytometric analysis was performed by use of a FACScan | (Becton Dickinson & Co., San Jose, CA) after staining of the 2.M2 cells (5 x 10 s) with 10/~g/ml of FITC-conjugated mouse IgE or 10/~g/ml of monoclonal anti-CD3e (2Cll) followed by FITC-conjugated rabbit anti-hamster antibody (Organon Teknika). For FcERI, the background staining was assessed by preincubation with 200/~g/ml of mouse IgE and for CD3/TCR by staining with the second antibody only.
In Vivo Phosphorylation, Immunoprecipitation, Two-dimensional Nonequilibrium pH Gel Electrophoresis (NEPHGE)-PAGE, SDS-PAGE, and Western Blotting. 2.M2 cells were incubated in phosphate-free medium for 4 h at 37~ and then labeled at 3 x 107 cells/ml with 37 MBq/ml [32p]orthophosphate for 2 h at 37~ The cells (2 x 107/ml) were incubated at 4~ for 30 rain with 10 #g/ml of antiFceRI c~ (BC4) or anti-CD3e (2Cll) monoclonal antibodies, and then stimulated for 2 min with medium alone or with 50/~g/ml of the appropriate second antibody, as indicated for individual experiments. The cells were then immediately washed and lysed as previously described (43) . The postnuclear supernatants were precleared with protein A-Sepharose beads, and then immunoprecipitated with antiphosphotyrosine monoclonal antibody bound to protein A-Sepharose. For two-dimensional analysis, the tyrosinephosphorylated proteins were loaded at the anode end of 6% acrylamide, 2% amphotine (pH 3.5-10) tube gels. Separation was performed for 6 h at 500 V. NEPHGE gels were equilibrated for 1 h with lx SDS sample buffer and then frozen at -70~ or applied directly on top of the second-dimension gels, which were run at 20 mA/gel. To show the tyrosine phosphorylation of the 3' chains, the proteins precipitated by antiphosphotyrosine antibody were eluted with phenylphosphate and the 3' chains immunoprecipitated with anti-3, antiserum. The samples were analyzed by SDS-PAGE (13.5% gel under reducing conditions) and autoradiography.
For Western blotting, 108 cells were lysed in a buffer containing 1% digitonin, 150 mM NaC1, 50 mM Hepes, pH 7.5, and protease and phosphatase inhibitors as previously described (43) . The postnuclear supernatants were immunoprecipitated and analyzed by SDS-PAGE as above, and the proteins were transferred electrophoretically to membranes (Immobilon-P; Millipore Corp., Bedford, MA) for 6 h at 50 V. Membranes were then incubated overnight in TBS (20 mM Tris, pH 7.5, 500 mM NaC1) containing 5% BSA before a 2-h incubation in the same buffer containing 1:200 dilution of anti-'), serum. After two washes in TTBS (TBS containing 0.1% Triton X-100 and 2.5% BSA), the membranes were incubated with 0.2 #g/ml goat anti-rabbit antibody conjugated to alkaline phosphatase and developed with the chemiluminescence substrate AMPPD according to the manufacturer.
11_,2 Production and Biological Assay.
For stimulation with 2Cll, flat-bottom 96-well microtiter plates (Costar Corp., Cambridge, MA) were coated with 50/zl of PBS containing 10/~g/ml of 2Cll (0.5/zg/well). For stimulation with BC4, microtiter wells were first precoated overnight at 4~ with 2.5 /~g/well of goat anti-mouse and then, after a 2-h saturation with 10% FBS in RPMI-1640, with 1/~g/well of BC4. After 2 h at room temperature and 1 h at 4~ the wells were washed three times with PBS, and 10 s cells in 250/zl of RPMI were added to each well. In all assays, after 24 h of culture, supernatants were collected and assayed for II~2 content by measuring the proliferation of Ib2-dependent murine T cells (CTLL). CTLL cells were incubated with IL2-ffee medium for 3 h at 37~ and then extensively washed with the same medium; 50-#1 aliquots (3 x 10 s cells/ml) were plated in 96-well microtiter plates with serial dilutions of supernatants. After 18 h at 37~ 1 #Ci of [3H]thymidine was added to each well for 6 h. [3H]Thymidine incorporation was quantitated by harvesting onto glass fiber filters by use ofa semiantomated cell harvester (LKB Wallac, Gaithersburg, MD) and by phdng the filters in a scintillation counter (Beta plate TM liquid scintillation counter; LKB Wallac) (NIH laboratory) or by direct 13 counting by use of gas ionization (Matrix 96 direct beta counter; Packard Instrument Co., Meriden, CT) (INSERM laboratory) (39) . The two different methods of quantitation explain the differences in the overall 3H counts observed with 2.M2 transfectants (NIH laboratory) and BW8 transfectants (INSERM laboratory). Results
Simultaneous Expression of FceRI and TCR/CD3 Complexes Containing Wild-type and Mutated 7 Chain Motifs on 2.M2
Cells. The cDNAs coding for FceRI o~, fl, and 3` chains were cotransfected into 2.M2 cells, a variant of the 2134 mouse T cell line which lacks TCK ~', TCK ,1, and FceKI 3' and, as a result, does not express TCK/CD3 complexes at the cell surface (28) . To identify 3, motif-controlled functions, we mutated the two intramotif tyrosines, which are required for activity (37, 38) , and we cotransfected the FceRI 3' mutant cDNA with FceRI ot and fl cDNAs (Fig. 1 A) . Cotransfection of FceKI oe and fl cDNAs with either wild-type or tyrosine-mutated 3' cDNA results in cell surface expression of FceRI receptors capable of binding IgE (Fig. 1 B, left) . Because the FceRI 3' chain can substitute for the absent TCR ~" chain (27) , the cotransfected cells also express surface TCK/ CD3 complexes (Fig. 1 B, right) . Two clones with wild-type 3` (WT23 and WT66) and three clones with tyrosine-mutated 3` (Y1, YS, and Yc) were used for further analysis.
The levels of the two reconstituted complexes containing wild-type 3` chains o~a clone WT23 are approximately equivalent, as shown by a binding assay using iodinated monodonal antibodies directed against Fcel~I ol (BC4) or CD3e (2Cll) (Fig. 1 C) or by FACS analysis (data not shown).
To demonstrate that both FcdLI and TCR/CD3 complexes contain FceRI ~/chains, total cell extracts from WT or Y transfectants were incubated with BC4 and 2Cll. The immunoprecipitates were then analyzed by SDS-PAGE followed by immunoblotting with anti-y or anti-~. The FceRI complexes in both transfectants contain equivalent amounts of 3, (Fig. 1/3) and B subunits (data not shown). Similarly, anti-3, immunoblotting of the anti-CD3e precipitates shows that the TCR/CD3 complexes associate equivalently with wildtype and tyrosine-mutated 3' chains (Fig. 1 D) . As expected, an anti-FceRI B immunoblot and an anti-TCR ~" immunoblot of the anti-CD3e precipitates did not detect any reactive bands (data not shown).
Engagement of TCR/CD3 and FceRI Induces Tyrosine Phosphorylation of the "f Chain.
To determine whether stimulation through reconstituted receptors activates early signaling events, we first studied whether cross-linking could induce the tyrosine phosphorylation of y. After in vivo labeling of the transfected 2.M2 cells with [32P]orthophosphate, FcdLI or TCR/CD3 complexes were engaged (or not) with relevant mAbs and then cross-linked with second antibodies. Phosphorylated proteins were eluted from an antiphosphotyrosine immunoprecipitate and reprecipitated with an anti-y antiserum before SDS-PAGE (Fig. 2) . Phosphorylation of both B and wild-type 3' chains occurred in activated FceRI (lane 2), as previously described in a mast cell line (43) . The wildtype 3' chain is also phosphorylated after TCR/CD3 engagement (lane 4). As expected, the phosphorylation of 3, is lost in both receptors when the tyrosines of ARAM-3, are mutated (lanes 6 and 8). Thus, each receptor complex is able to activate a tyrosine kinase capable of phosphorylating the "y chain. In addition, the fact that the mutation of the 3' chain does not affect the phosphorylation of the FceRI B chain (compare the 35-kD band in lanes 2 and 6) indicates that the kinase responsible for ~ phosphorylation is not under the control of ARAM-% This kinase is likely to be the Src family kinase Fyn because in vitro kinase assays after immunoprecipitation with anti-Fyn show an increase in kinase activity after aggregation of either FceRI or TCR/CD3 (data not shown).
The T Motif Associated with TCR/CD3 and FceRI Controls the Phosphorylation of Different Substrates in 2.M2, To further
our understanding of the role of the ~/motif in the activation of tyrosine kinases, we analyzed the tyrosine phosphorylation of the various substrates induced by the two receptor complexes. After engagement of FcdLI or TCR/CD3 complexes, the 32p-labeled phosphorylated proteins were immunoprecipitated with antiphosphotyrosine antibody and resolved by two dimensional gels, the first dimension being NEPHGE and the second SDS-PAGE (Fig. 3) (Fig. 3, E and F) . Most of these substrates are common to both CD3 and FceRI engagement (compare B and F). However, at least three substrates around 120 kD (e), 60 kD ~ and 140 kD (g) are reproducibly seen only after CD3 stimulation. Moreover, phosphorylation of these three substrates is completely abolished when the tyrosines of 3' are mutated (compare F and H). Therefore, the 3' motif in the context of TCR/CD3 controls the phosphorylation of these three substrates. The 42-kD acidic substrate d is also phosphorylated by the CD3 pathway, but its phosphorylation is not affected by tyrosine mutation of 3' and is therefore not under the control of the 3' motif in the context of TCR/CD3. Thus, the 3' motif in the context of the two receptors controls the phosphorylation of different substrates.
The 9/Motif Associated With Fc6RI but Not TCR/CD3 Is
Necessary to Mediate the Release of lL-2. We next investigated whether the 3' motif plays a role in a later activation event, the production of IL-2. Cross-linking of CD3 in both 2.M2 W T and Y transfectants induces IL-2 production. Two W T clones and 3 Y clones were analyzed two to three times each. Clone WT66 was always a higher producer than any other clone (Fig. 4 A) . This was not due to a higher level of expression of TCR/CD3, since these levels, which were tested by FACS before each experiment, were found comparable ( Fig.  1 B and data not shown) . Those results seem to indicate a slightly higher production of IL-2 by W T compared with Y, with a marked heterogeneity between clones.
The same experiments were performed with the BW~5 transfectants. Three W T clones and 3 Y-mutated clones were analyzed for IL-2 production after TCR engagement. Comparable levels of IL-2 were induced in the different clones (Fig. 4 B) . 
SN dil
Statistical calculations applied to similar experiments confirmed that no significant difference was present between the wildtype and tyrosine-mutated clones.
To test the significance of the heterogeneity in the response of WT and Y in 2.M2, which was not observed in BW& we applied the same statistical calculations to the results from 2.M2. When the comparison was performed between clones, that is, the various results from one clone obtained in various experiments were combined, there was no significant difference between WT and Y. We therefore conclude that the production of IL-2 after CD3 engagement does not require the integrity of the 3' motif.
When FceRI was engaged with multivalent antigen or with BC4 alone, no IL-2 secretion was observed (data not shown). However, reproducible IL-2 release was induced after FcERI engagement with high doses of BC4 bound to a crosslinking specific antibody coated to the 96-well plates (see Materials and Methods) (Fig. 4 C) . The IL-2 secretion was completely abolished when the tyrosines of 3' were mutated. Therefore, in the context of FceRI complexes, the presence of the 3, motif was necessary for initiating the signal cascade leading to IL-2 production.
Discussion
In this study, we have cotransfected a ]'-deficient T cell line with FceRI a, 13, and 3' cDNAs to induce the surface expression of two different FceRI "),-containing receptors, FceRI and TCR/CD3. The use of a wild-type FceRI "), chain and a mutated form, in which ARAM-3" had been inactivated by mutating its tyrosine residues to phenylalanine, has allowed us to specifically study the function of ARAM-3' in the context of the two different receptors. Both reconstituted TCR/CD3 and FceRI with the wild-type FceRI 3' chain are functional, as shown by their capacity to induce IL-2 release and to activate kinase(s).
The reconstituted FceRI with a tyrosine-mutated FceRI 3' loses its capacity to induce IL-2 release even though the 3 chain is phosphorylated and ubiquitinated upon triggering. Like the FceRI 3' chain, the 3 chain contains an ARAM in its COOH-terminal cytoplasmic tail. We have recently demonstrated that the FceRI 3' chain activates the kinase Syk, while 3 binds the Src family tyrosine kinase Lyn and controls receptor phosphorylation. This led us to propose a model in which the full signaling capacity of FceRI is achieved by cooperation between 3 and 3'. This model is supported by the results presented here. When the tyrosines of ARAM-3' are mutated, the 3 chain cannot initiate the full signaling repertoire of the entire receptor. However, by itself it can activate a tyrosine kinase, presumably the Src family kinase Fyn, responsible for the phosphorylation of 3 and other substrates. Taken together, the results presented here suggest a new classification for ARAMs: those able to Control late signals, like the ones in CD3, TCR ~', and FceRI 3", and those that do not, like the one in FceRI 3. This distinction should help in determining how ARAMs control the various arms of the signaling machinery.
In contrast with FceRI, the TCR/CD3 complex with a tyrosine-mutated FceRI "y is still able to induce IL-2 release upon aggregation. Therefore, the other ARAM-containing subunits of CD3 are capable of inducing IL-2 release independently. This could also explain the fact that one phosphorylated substrate, substrate d in Fig. 3 , requires an intact ARAM-3' when FceRI is activated but not when TCR/CD3 is activated. An alternative module in TCR/CD3 could substitute for the mutated ARAM-3" and promote the phosphorylation of substrate d. These results are in agreement with the findings that both CD3 e and ~" are capable of autonomously activating cells (39) , and that a TCR/CD3 complex can still induce IL-2 production despite the truncation of the cytoplasmic tail of ~" (36) . These previous reports have led to the concept of two parallel transducing units in the TCR/CD3 complex, the TCR ~'on the one hand and the CD3 complex on the other hand (39) . In this scenario, when FceRI 3' is mutated, the CD3 complex, in particular CD3 ~, would simply take over.
While the concept of two parallel transducing units in TCR/CD3 seems reasonable to explain the results discussed above, it does not satisfactorily explain some other results. At least three substrates, which are phosphorylated exclusively after TCR/CD3 engagement, disappear after mutation of FceRI 3' (Fig. 3) . Therefore, CD3 e is not capable of repladng FceRI 3' to mediate the phosphorylation of these substrates. The presence of FceRI 3' seems necessary. However, FceRI 3' does not mediate the phosphorylation of these three substrates after FceRI triggering. Therefore, FceRI 3' mediates the phosphorylation of these substrates, but only in the context of the TCR/CD3 complex. We propose that the environment of the FceRI 3' motif influences its capacity to mediate phosphorylation of various substrates. If one assumes that a substrate must associate, even temporarily, with the receptor complexes before phosphorylation, then the difference in substrates could be due to differences in recruitment by the two phosphorylated receptors. This, in turn, could be explained by the difference in subunit composition of the two receptors. Regardless of the mechanism that might explain the differences in substrate phosphorylation, our results clearly demonstrate that two different receptors with a common FceRI 3' ARAM expressed on the same cells can signal differently.
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